Results of high-dose treatment with autologous stem cell support in patients with multiple myeloma
- 31 July 2001
- journal article
- Published by Elsevier in Seminars in Hematology
- Vol. 38 (3) , 231-242
- https://doi.org/10.1016/s0037-1963(01)90015-0
Abstract
No abstract availableKeywords
This publication has 60 references indexed in Scilit:
- Multiple myeloma: the number of reinfused plasma cells does not influence outcome of patients treated with intensified chemotherapy and PBPC supportBone Marrow Transplantation, 2000
- Total Therapy With Tandem Transplants for Newly Diagnosed Multiple MyelomaBlood, 1999
- High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiencyBone Marrow Transplantation, 1997
- A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple MyelomaNew England Journal of Medicine, 1996
- Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/ autotransplantation and who were conventionally treated.Journal of Clinical Oncology, 1996
- Busulfan and melphalan as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myelomaBritish Journal of Haematology, 1995
- The Treatment of Multiple MyelomaNew England Journal of Medicine, 1994
- Gene-marking to trace origin of relapse after autologous bone-marrow transplantationThe Lancet, 1993
- Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patientsBlood, 1992
- Monoclonal antibody-purged autologous bone marrow transplantation therapy for multiple myelomaBlood, 1991